Seven Grand Managers LLC Makes New $685,000 Investment in Dyne Therapeutics, Inc. $DYN

Seven Grand Managers LLC bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 4th quarter, HoldingsChannel reports. The firm bought 35,000 shares of the company’s stock, valued at approximately $685,000.

Other hedge funds also recently bought and sold shares of the company. Chung Wu Investment Group LLC acquired a new stake in Dyne Therapeutics in the third quarter worth $30,000. Strs Ohio bought a new stake in shares of Dyne Therapeutics during the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after acquiring an additional 1,109 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after acquiring an additional 7,697 shares in the last quarter. Finally, Prudential Financial Inc. bought a new stake in shares of Dyne Therapeutics during the second quarter worth $111,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 287,956 shares of Dyne Therapeutics stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total value of $5,666,974.08. Following the completion of the transaction, the director owned 11,663 shares of the company’s stock, valued at $229,527.84. This trade represents a 96.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,559,462 shares of company stock valued at $29,814,746. Company insiders own 14.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DYN. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research report on Friday, May 15th. HC Wainwright lowered their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Sanford C. Bernstein increased their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Finally, Morgan Stanley lowered their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

Dyne Therapeutics Stock Up 0.1%

Dyne Therapeutics stock opened at $18.16 on Thursday. The company has a market cap of $3.00 billion, a P/E ratio of -5.64 and a beta of 1.08. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a fifty day simple moving average of $18.27 and a 200 day simple moving average of $18.31. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the company posted ($1.05) earnings per share. Research analysts anticipate that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.